On March 10, 2025, James F. Young, Ph.D. resigned from the Board of Directors (the “Board”) of Novavax, Inc. (the “Company”), effective as of March 10, 2025.
On March 10, 2025, the Board appointed John W. Shiver, Ph.D. to the Company’s Board, effective on such date, to fill the vacancy created by Dr. Young’s resignation and to serve as a Class III director for a term expiring at the Company’s 2025 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal.
Margaret G. McGlynn was appointed to serve as the Chairperson of the Board to succeed Dr. Young.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
James F. Young resigned as Chairperson of the Board at NOVAVAX INC.
Action
resigned
Role
Chairperson of the Board
Exact text from the filing
On March 10, 2025, James F. Young, Ph.D. resigned from the Board of Directors (the “Board”) of Novavax, Inc. (the “Company”), effective as of March 10, 2025.
John W. Shiver was appointed as Director at NOVAVAX INC.
Action
appointed
Role
Director
Exact text from the filing
On March 10, 2025, the Board appointed John W. Shiver, Ph.D. to the Company’s Board, effective on such date, to fill the vacancy created by Dr. Young’s resignation and to serve as a Class III director for a term expiring at the Company’s 2025 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.